drugset / Trial / NCT02957760
Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.
Phase 2
Unknown
30 enrolled
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
For Drug Consulting · collabHopital Universitaire Robert-Debre · collabInstitut National de la Transfusion Sanguine · collabKeyrus Biopharma · collabTheravia · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The central retinal vein occlusion (CRVO) is a major cause of ocular morbidity, depending in particular on the occurrence and extent of retinal ischemia by capillary occlusion. There is no effective systemic treatment of this condition. An increase in the adhesion of erythrocytes to vascular endothelium was observed for patients with CRVO, correlated with overexpression of membrane phosphatidylserine
Timeline
- Start
- 2015-12
- Primary completion
- 2017-08
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxyurea | Other / unclassified | 20 mg/kg | Oral |